These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 19196201)

  • 1. Vaccination concepts against Toxoplasma gondii.
    Garcia JL
    Expert Rev Vaccines; 2009 Feb; 8(2):215-25. PubMed ID: 19196201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.
    Innes EA; Vermeulen AN
    Parasitology; 2006; 133 Suppl():S145-68. PubMed ID: 17274844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toxoplasma gondii: perspectives for a vaccine].
    Gottstein B
    Schweiz Med Wochenschr Suppl; 1995; 65():89S-95S. PubMed ID: 7716458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against Toxoplasma gondii: an increasing priority for collaborative research?
    Innes EA
    Expert Rev Vaccines; 2010 Oct; 9(10):1117-9. PubMed ID: 20923261
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccines against Toxoplasma gondii: new developments and perspectives.
    Zhang NZ; Chen J; Wang M; Petersen E; Zhu XQ
    Expert Rev Vaccines; 2013 Nov; 12(11):1287-99. PubMed ID: 24093877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of toxoplasmosis vaccine development.
    Kur J; Holec-Gasior L; Hiszczyńska-Sawicka E
    Expert Rev Vaccines; 2009 Jun; 8(6):791-808. PubMed ID: 19485758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice.
    Peng GH; Yuan ZG; Zhou DH; He XH; Liu MM; Yan C; Yin CC; He Y; Lin RQ; Zhu XQ
    Vaccine; 2009 Nov; 27(47):6570-4. PubMed ID: 19720368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats.
    Frenkel JK; Pfefferkorn ER; Smith DD; Fishback JL
    Am J Vet Res; 1991 May; 52(5):759-63. PubMed ID: 1854103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii.
    Jongert E; de Craeye S; Dewit J; Huygen K
    Parasite Immunol; 2007 Sep; 29(9):445-53. PubMed ID: 17727568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice.
    Qu D; Wang S; Cai W; Du A
    Vaccine; 2008 Aug; 26(35):4541-8. PubMed ID: 18590785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii.
    Johnson LL; Lanthier P; Hoffman J; Chen W
    Vaccine; 2004 Sep; 22(29-30):4054-61. PubMed ID: 15364456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxoplasma gondii: prototype immunization of lambs against formation of muscle and brain cysts.
    Falcón J; Freyre A
    Vet Parasitol; 2009 Dec; 166(1-2):15-20. PubMed ID: 19729248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxoplasma gondii: protective effect of an intranasal SAG1 and MIC4 DNA vaccine in mice.
    Wang H; He S; Yao Y; Cong H; Zhao H; Li T; Zhu XQ
    Exp Parasitol; 2009 Jul; 122(3):226-32. PubMed ID: 19366622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens.
    Rosenberg C; De Craeye S; Jongert E; Gargano N; Beghetto E; Del Porto P; Vorup-Jensen T; Petersen E
    Vaccine; 2009 Apr; 27(18):2489-98. PubMed ID: 19368791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice.
    Zhang G; Huong VT; Battur B; Zhou J; Zhang H; Liao M; Kawase O; Lee EG; Dautu G; Igarashi M; Nishikawa Y; Xuan X
    Parasitology; 2007 Sep; 134(Pt 10):1339-46. PubMed ID: 17506929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii.
    Xue M; He S; Cui Y; Yao Y; Wang H
    Parasitol Int; 2008 Dec; 57(4):424-9. PubMed ID: 18562245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenetics of Toxoplasma gondii informs vaccine design.
    Henriquez FL; Woods S; Cong H; McLeod R; Roberts CW
    Trends Parasitol; 2010 Nov; 26(11):550-5. PubMed ID: 20580611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of modified live feline Toxoplasma gondii vaccine.
    Choromanski L; Freyre A; Popiel R; Brown K; Grieve R; Shibley G
    Dev Biol Stand; 1995; 84():269-81. PubMed ID: 7796964
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucosal vaccination against toxoplasmosis.
    Bout D; Buzoni-Gatel D; Chardès T; Debard N; Mevelec MN
    Vet Res; 1995; 26(3):214-5. PubMed ID: 7795682
    [No Abstract]   [Full Text] [Related]  

  • 20. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii.
    Garcia JL; Gennari SM; Navarro IT; Machado RZ; Sinhorini IL; Freire RL; Marana ER; Tsutsui V; Contente AP; Begale LP
    Vet Parasitol; 2005 May; 129(3-4):209-17. PubMed ID: 15845275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.